Patients with EGFR-mutated metastatic NSCLC research hub

Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (OSIBBBOOST)

This study looks at how a lung cancer drug, osimertinib (Tagrisso), gets into the brain and spinal fluid. Researchers want to see if adding another drug, febuxostat (Adenuric), can help more osimertinib reach these areas, which might improve treatment for some patients.